BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

BXPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

BXPHARMA 29-Jan-2020

(Q2 Un-audited): Consolidated EPS was Tk. 2.12 for October-December 2019 as against Tk. 1.81 for October-December 2018; Consolidated EPS was Tk. 4.26 for July-December 2019 as against Tk. 3.67 for July-December 2018. Consolidated NOCFPS was Tk. 9.14 for July-December 2019 as against Tk. 2.10 for July-December 2018. Consolidated NAV per share was Tk. 75.66 as on December 31, 2019 and Tk. 69.15 as on December 31, 2018.

BXPHARMA 21-Jan-2020

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 28, 2020 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2019.

BXPHARMA 30-Jan-2019

(Q2 Un-audited): Consolidated EPS was Tk. 1.81 for October-December, 2018 as against Tk. 1.66 for October-December, 2017; Consolidated EPS was Tk. 3.67 for July-December, 2018 as against Tk. 3.25 for July-December, 2017. Consolidated NOCFPS was Tk. 2.10 for July-December, 2018 as against Tk. 3.14 for July-December, 2017. Consolidated NAV per share was Tk. 69.15 as on December 31, 2018 and Tk. 63.77 as on December 31, 2017.

BXPHARMA 23-Jan-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2019 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2018.

BXPHARMA 29-Jan-2018

(Q2 Un-audited): EPS was Tk. 1.66 for October-December, 2017 as against Tk. 1.47 for October-December, 2016; EPS was Tk. 3.25 for July-December, 2017 as against Tk. 2.74 for July-December, 2016. NOCFPS was Tk. 3.14 for July-December, 2017 as against Tk. 2.56 for July-December, 2016. NAV per share was Tk. 63.77 as on December 31, 2017 and Tk. 59.07 as on December 31, 2016.

BXPHARMA 22-Jan-2018

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2018 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2017. Post Date: 2018-01-22

BXPHARMA 08-Oct-2017

(continuation news of BXPHARMA): with a local manufacturing facility at Tongi, Gazipur. They also have a long-term manufacturing and marketing collaboration with Merck Sharp & Dohme (MSD). According to the Quintiles IMS Q2 2017 data of the retail pharma market in Bangladesh, Nuvista Pharma currently ranks as the 21st largest supplier to the market by volume. (end)

BXPHARMA 26-Jan-2017

(Q2 Un-audited): EPS was Tk. 1.47 for October-December, 2016 as against Tk. 1.29 for October-December, 2015; EPS was Tk. 2.74 for July-December, 2016 as against Tk. 2.33 for July-December, 2015. NOCFPS was Tk. 2.56 for July-December, 2016 as against Tk. 3.28 for July-December, 2015. NAV per share was Tk. 59.07 as of December 31, 2016 and Tk. 58.20 as of December 31, 2015.

BXPHARMA 22-Jan-2017

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 26, 2017 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2016.

Previous Next page